FGF21-based pharmacotherapy--potential utility for metabolic disorders - PubMed (original) (raw)

Review

FGF21-based pharmacotherapy--potential utility for metabolic disorders

Ruth E Gimeno et al. Trends Endocrinol Metab. 2014 Jun.

Abstract

Currently available therapies for diabetes or obesity produce modest efficacy and are usually used in combination with agents targeting cardiovascular risk factors. Fibroblast growth factor 21 (FGF21) is a circulating protein with pleiotropic metabolic actions; pharmacological doses of FGF21 produce anti-diabetic, lipid-lowering, and weight-reducing effects in rodents. Several potential benefits have translated to non-human primates and obese humans with type 2 diabetes (T2D). Accumulating results point to a specific receptor complex and actions in adipose tissue, liver, and brain; several pathways lead to enhanced fatty acid oxidation, increased insulin sensitivity, and augmented energy expenditure. A range of strategies are being explored to derive potent, safe, and convenient therapies which could potentially represent novel approaches to prevent and treat a variety of metabolic disorders.

Copyright © 2014 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Similar articles

• Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
  Woo YC, Xu A, Wang Y, Lam KS. Woo YC, et al. Clin Endocrinol (Oxf). 2013 Apr;78(4):489-96. doi: 10.1111/cen.12095. Clin Endocrinol (Oxf). 2013. PMID: 23134073 Review.
• Fibroblast growth factor-21, energy balance and obesity.
  Giralt M, Gavaldà-Navarro A, Villarroya F. Giralt M, et al. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:66-73. doi: 10.1016/j.mce.2015.09.018. Epub 2015 Sep 26. Mol Cell Endocrinol. 2015. PMID: 26415590 Review.
• Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus.
  Dostálová I, Haluzíková D, Haluzík M. Dostálová I, et al. Physiol Res. 2009;58(1):1-7. doi: 10.33549/physiolres.931610. Physiol Res. 2009. PMID: 19331512 Review.
• Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
  So WY, Leung PS. So WY, et al. Med Res Rev. 2016 Jul;36(4):672-704. doi: 10.1002/med.21390. Epub 2016 Mar 31. Med Res Rev. 2016. PMID: 27031294 Review.
• Impact of FGF21 on glycemic control.
  Strowski MZ. Strowski MZ. Horm Mol Biol Clin Investig. 2017 Jun 3;30(2):/j/hmbci.2017.30.issue-2/hmbci-2017-0001/hmbci-2017-0001.xml. doi: 10.1515/hmbci-2017-0001. Horm Mol Biol Clin Investig. 2017. PMID: 28593912 Review.

Cited by

• FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice.
  Stemmer K, Zani F, Habegger KM, Neff C, Kotzbeck P, Bauer M, Yalamanchilli S, Azad A, Lehti M, Martins PJ, Müller TD, Pfluger PT, Seeley RJ. Stemmer K, et al. Diabetologia. 2015 Oct;58(10):2414-23. doi: 10.1007/s00125-015-3668-7. Epub 2015 Jun 23. Diabetologia. 2015. PMID: 26099854 Free PMC article.
• A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution.
  Maida A, Zota A, Sjøberg KA, Schumacher J, Sijmonsma TP, Pfenninger A, Christensen MM, Gantert T, Fuhrmeister J, Rothermel U, Schmoll D, Heikenwälder M, Iovanna JL, Stemmer K, Kiens B, Herzig S, Rose AJ. Maida A, et al. J Clin Invest. 2016 Sep 1;126(9):3263-78. doi: 10.1172/JCI85946. Epub 2016 Aug 22. J Clin Invest. 2016. PMID: 27548521 Free PMC article.
• The Sweet Path to Metabolic Demise: Fructose and Lipid Synthesis.
  Herman MA, Samuel VT. Herman MA, et al. Trends Endocrinol Metab. 2016 Oct;27(10):719-730. doi: 10.1016/j.tem.2016.06.005. Epub 2016 Jul 4. Trends Endocrinol Metab. 2016. PMID: 27387598 Free PMC article. Review.
• Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis.
  Anthony SR, Guarnieri AR, Gozdiff A, Helsley RN, Phillip Owens A, Tranter M. Anthony SR, et al. Clin Sci (Lond). 2019 Nov 29;133(22):2329-2344. doi: 10.1042/CS20190578. Clin Sci (Lond). 2019. PMID: 31777927 Free PMC article. Review.
• Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges.
  Martínez-Garza Ú, Torres-Oteros D, Yarritu-Gallego A, Marrero PF, Haro D, Relat J. Martínez-Garza Ú, et al. Int J Mol Sci. 2019 Sep 21;20(19):4692. doi: 10.3390/ijms20194692. Int J Mol Sci. 2019. PMID: 31546675 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information